Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020117929 - METHODS AND COMPOSITIONS FOR TREATING ASTHMA

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]

CLAIMS

1) A method of treating asthma, the method comprising administering to a subject in need thereof an effective amount of an agent that inhibits the IL-6 signaling.

2) The method of claim 1, wherein the asthma is pediatric asthma.

3) The method of claim 1 or 2, wherein the asthma is non-atopic asthma.

4) The method of any of claims 1-3, wherein the asthma is severe, persistent asthma.

5) The method of claim 1, further comprising, prior to administration, diagnosing a subject with having asthma.

6) The method of any of claims 1-5, wherein the subject has a mutation in the IL4R gene.

7) The method of claim 6, wherein the subject is a homozygous for IL4R dominant allele.

8) The method of claim 6, wherein the subject is a homozygous for IL4R mutant allele.

9) The method of claim 1, further comprising, prior to administration, identifying a subject as having a mutation in the IL4R gene.

10) The method of claim 1, further comprising, prior to administration, receiving results that identify a subject as having a mutation in the IL4R gene.

11) The method of claim 1, wherein the agent that inhibits IL-6 signaling is selected from the group consisting of a small molecule, an antibody, a peptide, a genome editing system, an antisense oligonucleotide, and an RNAi.

12) The method of claim 11, wherein the RNAi is a microRNA, an siRNA, or a shRNA.

13) The method of claim 11, wherein the antibody is a humanized antibody.

14) The method of claim 13, wherein the humanized antibody is tocilizumab.

15) The method of any of claim 11-14, wherein the agent targets IL-6 or IL-6 receptor (IL-6R).

16) The method of any of claim 1, wherein inhibiting IL-6 or IL-6R is inhibiting the expression level and/or activity of IL-6 or IL-6R.

17) The method of claim 16, wherein the expression level and/or activity of IL-6 or IL-6R is inhibited by at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more as compared to an appropriate control.

18) The method of claim 1, wherein administration decreases circulation of a cell selected from the group consisting of: a IL-4+Foxp3+ (TH2-like) T regulatory cell, a IL-17+Foxp3+ (TH17-like) T regulatory cell, a TH2 cell, and a TH17 cell.

19) The method of claim 18, wherein circulation is decreased by at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more as compared to an appropriate control.

20) The method of claim 1, wherein the agent is administered at a concentration of 8mg/kg or lOmg/kg.

21) The method of claim 1, further comprising administering at least a second asthma therapeutic.

22) A method of treating asthma, the method comprising administering to a subject in need thereof an effective amount of tocilizumab.

23) The method of claim 22, wherein the asthma is pediatric asthma.

24) The method of claim 22 or 23, wherein the asthma is non-atopic asthma.

25) The method of any of claims 22-24, wherein the asthma is severe, persistent asthma.

26) The method of claim 22, further comprising, prior to administration, diagnosing a subject with having asthma.

27) The method of any of claims 22-26, wherein the subject has a mutation in the IL4R gene.

28) The method of claim 27, wherein the subject is a homozygous for IL4R dominant allele. 29) The method of claim 27, wherein the subject is a homozygous for IL4R mutant allele.

30) The method of claim 22, further comprising, prior to administration, identifying a subject as having a mutation in the IL4R gene.

31) The method of claim 22, further comprising, prior to administration, receiving results that identify a subject as having a mutation in the IL4R gene.

32) The method of claim 22, wherein tocilizumab is administered at a concentration of 8mg/kg or lOmg/kg.

33) The method of claim any of claims 22-32, wherein tocilizumab is administered once every 2 weeks or once every 4 weeks.

34) The method of claim 22, wherein administration decreases circulation of a cell selected from the group consisting of: a IL-4+Foxp3+ (TH2-like) T regulatory cell, a IL-17+Foxp3+ (TH17-like) T regulatory cell, a TH2 cell, and a TH17 cell.

35) The method of claim 34, wherein circulation is decreased by at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more as compared to an appropriate control.

36) The method of claim 22, further comprising administering at least a second asthma therapeutic.

37) A composition comprising an agent that inhibits IL-6 signaling.

38) The composition of claim 37, further comprising a pharmaceutically acceptable carrier.